BMRA vs BRTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating extremely weak fundamental health. Despite a seemingly healthy Current Ratio of 3.25 and low Debt/Equity of 0.06, the company is plagued by deep profitability issues, including a -90.31% profit margin and -84.30% ROE. Revenue has declined by 26% year-over-year, and the stock has lost 95.7% of its value over five years, reflecting persistent operational failures and lack of investor confidence. The absence of an Altman Z-Score due to incomplete data further limits confidence in solvency assessments, but the overwhelming negative trends in earnings, margins, and price performance dominate the outlook.
BRTX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
BMRA vs BRTX: Head-to-Head Comparison
This page compares Biomerica, Inc. (BMRA) and BioRestorative Therapies, Inc. (BRTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.